系统性红斑狼疮认知功能障碍:启动临床试验的必要性
本文综述了系统性红斑狼疮(SLE)相关认知功能障碍(CD)的流行病学、发病机制、评估困境与潜在治疗方向。CD在SLE中隐匿且诊断不足,患病率报告为5%至80%,与细胞因子、炎症分子及抗体相关,可能通过破坏血脑屏障及神经毒性、小胶质细胞激活介导。目前无针对SLE相关CD的治疗,潜在候选药物包括抑制小胶质细胞激活的血管紧张素转换酶抑制剂或保护血脑屏障的C5a受体阻滞剂,神经影像异常与CD相关并可能成为未来临床试验的诊断工具和结局指标。
要点
- SLE相关认知功能障碍患病率报告为5%至80%,评估方式不一致且归因困难。
- CD与已知疾病机制相关,涉及细胞因子、炎症分子和抗体介导的神经元损伤。
- 目前无针对SLE相关CD的治疗,潜在候选包括ACEI和C5a受体阻滞剂。
核心结论
- SLE相关认知功能障碍是隐匿且诊断不足的表现,对生活质量有显著影响,已有强证据支持其与已知疾病机制相关,应启动临床试验。
研究设计与样本
- 本文为综述,未报告系统检索范围或样本量。
主要发现
- CD的患病率报告范围为5%至80%,原因包括评估模式不一致及归因于SLE的困难。
- 小鼠模型和临床数据均显示CD与已知疾病机制相关。
- 多种细胞因子、炎症分子和抗体与CD相关。
- 抗体和细胞因子介导神经元损伤的机制包括血脑屏障完整性破坏、循环可溶性分子直接入脑及随后的神经毒性和小胶质细胞激活。
- SLE患者的结构和功能神经影像显示代谢及白质微结构完整性存在区域性异常,与CD相关。
关键数值与推荐
- 原文未报告具体诊断标准或数值阈值。
临床怎么用
- 临床应关注SLE患者认知功能障碍的筛查与评估,但需注意现有评估方式的不一致性。
- 潜在治疗方向包括抑制小胶质细胞激活的血管紧张素转换酶抑制剂或保护血脑屏障的C5a受体阻滞剂。
- 神经影像异常可能在未来成为临床试验中的诊断工具和结局指标。
局限性
- 临床研究受限于受试人群异质性及缺乏敏感、标准化的认知测试或其他经验证的客观生物标志物。
- CD的归因于SLE存在困难,评估模式不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cognitive dysfunction (CD) is an insidious and underdiagnosed manifestation of systemic lupus erythematosus (SLE) that has a considerable impact on quality of life, which can be devastating. Given the inconsistencies in the modes of assessment and the difficulties in attribution to SLE, the reported prevalence of CD ranges from 5% to 80%. Although clinical studies of SLE-related CD have been hampered by heterogeneous subject populations and a lack of sensitive and standardized cognitive tests or other validated objective biomarkers for CD, there are, nonetheless, strong data from mouse models and from the clinical arena that show CD is related to known disease mechanisms. Several cytokines, inflammatory molecules, and antibodies have been associated with CD. Proposed mechanisms for antibody- and cytokine-mediated neuronal injury include the abrogation of blood-brain barrier integrity with direct access of soluble molecules in the circulation to the brain and ensuing neurotoxicity and microglial activation. No treatments for SLE-mediated CD exist, but potential candidates include agents that inhibit microglial activation, such as angiotensin-converting enzyme inhibitors, or that protect blood-brain barrier integrity, such as C5a receptor blockers. Structural and functional neuroimaging data have shown a range of regional abnormalities in metabolism and white matter microstructural integrity in SLE patients that correlate with CD and could in the future become diagnostic tools and outcome measures in clinical trials aimed at preserving cognitive function in SLE.
引用
- Kello N, Anderson E, Diamond B, et al. Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials. Arthritis Rheumatol. 2019. PMID: 31102496. doi:10.1002/art.40933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。